Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
AOD-9604 may be appropriate for individuals seeking research-based approaches to body composition optimization under physician supervision
Dosage matched to delivery method matched to goal
In the Phase 2 clinical trial (NEJM, 2023), retatrutide was administered subcutaneously at doses ranging from approximately 0.5 mg to 12 mg per week, with dose escalation under close medical supervision
Canlab Research cannot advertise (or assist others in advertising) these products, including on any website or social media platform accessible with a Canadian Internet Protocol (IP) address
1 The clinical treatment of skin loss due to severe and massive burns or wounds continues to be a major problem in surgical procedures
US$ 29.65
,aspect=ignore)
US$ 28.22
US$ 27.75
